FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204253855> ?p ?o ?g. }

• W3204253855 abstract "Introduction: The incidence of acute kidney injury (AKI) related to vancomycin is variable, and several risk factors related to the treatment and patients may explain the nephrotoxicity. The role of urinary biomarkers in AKI related to vancomycin is unknown. Objective: The aim of this study was to evaluate the role of urinary IL-18, KIM-1, NGAL, TIMP-2, and IGFBP7 as diagnostic and prognostic predictors of AKI related to vancomycin. Methods: A prospective cohort study of patients receiving vancomycin and admitted to wards of a public university hospital from July 2019 to May 2020 was performed. We excluded patients that had AKI before starting vancomycin, hemodynamic instability, inability to collect urine, and chronic kidney disease stage 5. Results: Ninety-four patients were included, and the prevalence of AKI was 24.5%, while the general mortality was 8.7%. AKI occurred 11 ± 2 days after the first vancomycin dose. The most frequent KDIGO stage was 1 (61%). There was no difference between patients who developed and did not develop AKI due to gender, length of hospital stay, dose, and time of vancomycin use. Logistic regression identified age (OR 6.6, CI 1.16–38.22, p = 0.03), plasmatic vancomycin concentrations between 96 and 144 h (OR 1.18, CI 1.04-1.40, p = 0.04), and urinary NGAL levels between 96 and 144 h (OR 1.123, CI 1.096–1.290, p = 0.03) as predictors of AKI. The time of vancomycin use (OR 4.61, CI 1.11–22.02, p = 0.03), higher plasmatic vancomycin concentrations between 192 and 240 h (OR 1.02, CI 0.98–1.06, p = 0.26), and higher cell cycle arrest urinary biomarkers TIMP-2 multiplied by IGFBP-7 between 144 and 192 h (OR 1.33, CI 1.10–1.62, p = 0.02; OR 1.19, CI 1.09–1.39, p = 0.04, respectively) were identified as prognostic factors for non-recovery of kidney function at discharge. Conclusion: AKI related to vancomycin was frequent in patients hospitalized in wards. Age, plasmatic vancomycin concentrations, and NGAL between 96 and 144 h were identified as predictors of AKI related to vancomycin use. Plasmatic vancomycin concentrations and urinary NGAL were predictors of AKI diagnosis within the next 5 days. The urinary biomarkers of cell cycle arrest TIMP-2 and IGFBP-7 and the duration of vancomycin use were associated with non-recovery of kidney function at hospital discharge moment." @default.
• W3204253855 created "2021-10-11" @default.
• W3204253855 creator A5000041043 @default.
• W3204253855 creator A5002486385 @default.
• W3204253855 creator A5027688105 @default.
• W3204253855 creator A5028923673 @default.
• W3204253855 creator A5051389313 @default.
• W3204253855 creator A5067567259 @default.
• W3204253855 creator A5068747774 @default.
• W3204253855 date "2021-09-23" @default.
• W3204253855 modified "2023-10-01" @default.
• W3204253855 title "The Role of Urinary Biomarkers as Diagnostic and Prognostic Predictors of Acute Kidney Injury Associated With Vancomycin" @default.
• W3204253855 cites W1545074211 @default.
• W3204253855 cites W1987417671 @default.
• W3204253855 cites W2007193748 @default.
• W3204253855 cites W2018115918 @default.
• W3204253855 cites W2042841791 @default.
• W3204253855 cites W2065582745 @default.
• W3204253855 cites W2069859988 @default.
• W3204253855 cites W2093562100 @default.
• W3204253855 cites W2111442039 @default.
• W3204253855 cites W2114828210 @default.
• W3204253855 cites W2127477439 @default.
• W3204253855 cites W2129326184 @default.
• W3204253855 cites W2133120422 @default.
• W3204253855 cites W2148152947 @default.
• W3204253855 cites W2155965977 @default.
• W3204253855 cites W2314507682 @default.
• W3204253855 cites W2442891917 @default.
• W3204253855 cites W2474420458 @default.
• W3204253855 cites W2489050915 @default.
• W3204253855 cites W2555652234 @default.
• W3204253855 cites W2560205629 @default.
• W3204253855 cites W2565205631 @default.
• W3204253855 cites W2745271987 @default.
• W3204253855 cites W2769033381 @default.
• W3204253855 cites W2789362789 @default.
• W3204253855 cites W2795495112 @default.
• W3204253855 cites W3005462992 @default.
• W3204253855 cites W3089762823 @default.
• W3204253855 cites W49170394 @default.
• W3204253855 doi "https://doi.org/10.3389/fphar.2021.705636" @default.
• W3204253855 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8495315" @default.
• W3204253855 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34630082" @default.
• W3204253855 hasPublicationYear "2021" @default.
• W3204253855 type Work @default.
• W3204253855 sameAs 3204253855 @default.
• W3204253855 citedByCount "7" @default.
• W3204253855 countsByYear W32042538552022 @default.
• W3204253855 countsByYear W32042538552023 @default.
• W3204253855 crossrefType "journal-article" @default.
• W3204253855 hasAuthorship W3204253855A5000041043 @default.
• W3204253855 hasAuthorship W3204253855A5002486385 @default.
• W3204253855 hasAuthorship W3204253855A5027688105 @default.
• W3204253855 hasAuthorship W3204253855A5028923673 @default.
• W3204253855 hasAuthorship W3204253855A5051389313 @default.
• W3204253855 hasAuthorship W3204253855A5067567259 @default.
• W3204253855 hasAuthorship W3204253855A5068747774 @default.
• W3204253855 hasBestOaLocation W32042538551 @default.
• W3204253855 hasConcept C120665830 @default.
• W3204253855 hasConcept C121332964 @default.
• W3204253855 hasConcept C126189478 @default.
• W3204253855 hasConcept C126322002 @default.
• W3204253855 hasConcept C177713679 @default.
• W3204253855 hasConcept C188816634 @default.
• W3204253855 hasConcept C2778653478 @default.
• W3204253855 hasConcept C2778980435 @default.
• W3204253855 hasConcept C2779489039 @default.
• W3204253855 hasConcept C2780091579 @default.
• W3204253855 hasConcept C2780472472 @default.
• W3204253855 hasConcept C523546767 @default.
• W3204253855 hasConcept C54355233 @default.
• W3204253855 hasConcept C61511704 @default.
• W3204253855 hasConcept C71924100 @default.
• W3204253855 hasConcept C77411442 @default.
• W3204253855 hasConcept C86803240 @default.
• W3204253855 hasConceptScore W3204253855C120665830 @default.
• W3204253855 hasConceptScore W3204253855C121332964 @default.
• W3204253855 hasConceptScore W3204253855C126189478 @default.
• W3204253855 hasConceptScore W3204253855C126322002 @default.
• W3204253855 hasConceptScore W3204253855C177713679 @default.
• W3204253855 hasConceptScore W3204253855C188816634 @default.
• W3204253855 hasConceptScore W3204253855C2778653478 @default.
• W3204253855 hasConceptScore W3204253855C2778980435 @default.
• W3204253855 hasConceptScore W3204253855C2779489039 @default.
• W3204253855 hasConceptScore W3204253855C2780091579 @default.
• W3204253855 hasConceptScore W3204253855C2780472472 @default.
• W3204253855 hasConceptScore W3204253855C523546767 @default.
• W3204253855 hasConceptScore W3204253855C54355233 @default.
• W3204253855 hasConceptScore W3204253855C61511704 @default.
• W3204253855 hasConceptScore W3204253855C71924100 @default.
• W3204253855 hasConceptScore W3204253855C77411442 @default.
• W3204253855 hasConceptScore W3204253855C86803240 @default.
• W3204253855 hasLocation W32042538551 @default.
• W3204253855 hasLocation W32042538552 @default.
• W3204253855 hasLocation W32042538553 @default.
• W3204253855 hasLocation W32042538554 @default.
• W3204253855 hasOpenAccess W3204253855 @default.
• W3204253855 hasPrimaryLocation W32042538551 @default.
• W3204253855 hasRelatedWork W1974538653 @default.

• next